LeonaBio, Inc. SEC filings document the company’s status as a Delaware clinical-stage biopharmaceutical issuer listed on The Nasdaq Capital Market under the LONA ticker. Its 8-K reports furnish financial results, business updates, Regulation FD disclosures, board matters, and material events tied to its product candidates and corporate development activity.
Registration statement amendments cover delayed or continuous securities offerings, while amended material-event filings document the completed Sermonix license transaction, related securities issuance, and SEC accounting disclosures under Regulation S-X. The filing record also reflects the company’s transition from Athira Pharma to LeonaBio and the capital-structure disclosures associated with its common stock and warrants.
LeonaBio, Inc. is a clinical-stage biopharmaceutical company developing lasofoxifene for ESR1-mutated metastatic breast cancer and brelgometon for ALS. For the six months ended June 30, 2026, it reported a net loss of $51.9 million, significantly higher than $16.1 million a year earlier, driven by much higher research and development and general and administrative spending.
Cash, cash equivalents and investments totaled $51.1 million at June 30, 2026, down from $69.9 million at year-end, with $37.9 million used in operating activities in the first half. The company states that existing liquidity may not fund operations for at least 12 months, raising substantial doubt about its ability to continue as a going concern.
LeonaBio raised $90.0 million in a December 2025 PIPE, issuing common stock and multiple warrant classes, including 23.0 million Series A Common Warrants that, if fully exercised, could provide an additional $146.2 million. A 5.5 million-share Sermonix pre-funded warrant was reclassified from liability to equity after stockholder approval, eliminating a large fair value liability from the balance sheet.
LeonaBio reported results for the quarter ended June 30, 2026 and highlighted progress across its oncology and neurodegeneration pipeline. The company’s lead program, lasofoxifene, is being evaluated in the Phase 3 ELAINE-3 trial in ER-positive, HER2-negative, ESR1‑mutated metastatic breast cancer in combination with abemaciclib. Enrollment has reached 495 patients, and LeonaBio expects to complete enrollment of approximately 600 participants in 4Q 2026, with topline data expected in the second half of 2027.
Lasofoxifene previously showed encouraging activity in the Phase 2 ELAINE‑1 and ELAINE‑2 studies, and LeonaBio is investing in CMC, regulatory and commercial readiness ahead of potential approval. The company also advanced brelgometon (ATH‑1105), which completed a first‑in‑human Phase 1 trial in 80 healthy volunteers, demonstrating favorable safety, tolerability and CNS penetration, supporting a planned Phase 2 proof‑of‑concept trial in ALS.
Cash, cash equivalents and investments were $51.1 million as of June 30, 2026. Net cash used in operations was $37.9 million for the quarter. Research and development expenses rose to $12.9 million, general and administrative expenses to $6.6 million, and net loss to $19.0 million, or $0.80 per share. The company points to up to an additional $146 million in potential proceeds from cash‑exercisable warrants issued in its December 2025 financing as a key funding source for upcoming milestones.
LeonaBio, Inc. reported a Form 4 showing a grant of stock options covering 28,000 shares of common stock to a board designee associated with Perceptive Advisors. The options have an exercise price of $9.54 per share and expire on April 8, 2036, vesting monthly over 24 months while the optionee continues as a Service Provider.
LeonaBio, Inc. reported a Form 4 showing an option grant related to director compensation. Entities associated with director Joseph Edelman received a stock option covering 28,000 shares of common stock at an exercise price of $8.35 per share. The option vests on the earlier of June 23, 2027 or the day before the next annual stockholder meeting after June 22, 2026, and expires on June 22, 2036. The grant was made under LeonaBio’s Outside Director Compensation Policy, with Perceptive entities having an indirect pecuniary interest through a management fee offset and disclaiming beneficial ownership except to that extent.
LeonaBio, Inc. director Fred Callori received a grant of stock options covering 2,333 shares of common stock at an exercise price of $8.35 per share. These options vest on the earlier of June 23, 2027 or just before the next annual stockholder meeting after June 22, 2026 and expire on June 22, 2036.
LeonaBio, Inc. director Natalie C. Holles received a grant of stock options covering 2,333 shares of common stock. The options have an exercise price of $8.35 per share and are held as a direct ownership position.
According to the grant terms, these options vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. The grant was issued under LeonaBio’s Outside Director Compensation Policy and was pro-rated based on her appointment to the board on May 5, 2026. After this grant, her reported option holdings from this award total 2,333 shares and expire on June 22, 2036.
LeonaBio, Inc. director Peter B. Silverman received a grant of stock options covering 2,333 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting held after June 22, 2026. The award was granted under LeonaBio’s Outside Director Compensation Policy and pro-rated based on his board appointment on May 5, 2026.
LeonaBio, Inc. director Michael A. Panzara received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. This is a compensation-related award rather than an open-market transaction.
LeonaBio, Inc. director Romano Kelly reported receiving a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholders’ meeting that occurs after June 22, 2026. The grant was made under LeonaBio’s Outside Director Compensation Policy and reflects equity-based compensation rather than an open-market purchase or sale.
LeonaBio, Inc. director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock at an exercise price of $8.35 per share. The options expire on June 22, 2036 and vest on the earlier of June 23, 2027 or the day before the next annual stockholder meeting after June 22, 2026, under the company’s Outside Director Compensation Policy.